Calliditas Therapeutics names new vice president, North America Commercial
9 January 2019 -

Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX), a specialty pharmaceutical company based in Stockholm, Sweden, announced yesterday that it has named Andrew Udell as its new vice president, North America Commercial, effective 1 February 2019.

Udell will be part of the management team and has more than two decades of commercial and marketing experience in the biotechnology and pharmaceutical industries.

Prior to joining Calliditas, Udell served as vice president of Commercial for North America at Neuroderm Ltd. He previously served in commercial leadership roles in the biotech industry, including at Intrexon Corporation as vice president, Marketing and Communications, and as vice president of Marketing at Clinical Data Inc., where he was responsible for the US commercial launch of the company's flagship product, Viibryd, a novel antidepressant. He also spent a decade working in several sales and marketing leadership roles at Purdue Pharma, ultimately leading a cross-functional team for a USD2bn pain medication franchise.